Sun Pharmaceutical Industries Ltd.’s psoriasis asset, Ilumya (tildrakizumab), has made inroads into the US psoriasis market, garnering early attention from some physicians despite being up against formidable competition.
Ilumya has been well received, with close to 800 physicians having prescribed the product to date, Sun says. The Indian...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
